Safety of oral iron chelator deferiprone in young thalassaemics

European Journal of Haematology

Volumn 74, Issue 3, 2005, Pages 217-220

  Naithani, Rahul ^a,b   Chandra, Jagdish ^a   Sharma, Sharad ^a  

^a KALAWATI SARAN CHILDREN'S HOSPITAL   (India)

^b NONE   (India)

Author keywords

Children; Deferiprone; Iron chelation; Thalassaemia

Indexed keywords

DEFERIPRONE; IRON CHELATING AGENT;

AGRANULOCYTOSIS; ARTHRALGIA; ARTHRITIS; ARTICLE; BLEEDING; BLOOD CELL COUNT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; IRON CHELATION; NAUSEA AND VOMITING; NEUTROPENIA; OSTEOARTHROPATHY; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA; THROMBOCYTOPENIA;

BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRON CHELATING AGENTS; JOINT DISEASES; MALE; NAUSEA; NEUTROPENIA; PYRIDONES; THALASSEMIA; THROMBOCYTOPENIA; VOMITING;

EID: 14044266868     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00377.x     Document Type: Article

References (20)

1. MOESCHLIN S, SCHNIDER U. Treatment of primary and secondary hemochromatosis and acute iron poisoning with a new, potent iron-eliminating agent (desferrioxamine-B). N Engl J Med 1963;269:57-66.
2. GABUTTI V, BOGNA-PIGNATTI C. Clinical manifestations and therapy of transfusional haemosiderosis. Baillieres Clin Haematol 1994;7:919-940.
3. OLIVERI NF, BRITTENHAM GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
4. AL-REFAIE EN, HERSHKO C, HOFFBRAND AV, KOSARYAN M, OLIVIERI NE, TONDURY P, WONKE B. Results of long term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelator. Br J Haematol 1995;91:224-229.
5. CECI A, BALARDI P, FELISI M, et al. The safety and effectiveness of deferiprone in a large scale, 3 year study in Italian patients. Br J Haematol 2002;118:330-336.
6. COHEN AR., GALANELLO R, PIGA A, SANCTIS VD, TRICTA F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587.
7. AGARWAL MB, GUPTE SS, VISWANATHAN C, VASANDANI D, RAMANATHAN J, DESAI N, PUNIYANI RR, CHHABLANI AT. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460-466.
8. AL REFAIE EN., WONKE B, HOFFBRAND AV., WICKENS DG., NORTEY P, KONTOGHIORGHES GJ. Efficacy and possible adverse effects of the oral iron chelator 1.2 dimethyl-3-hydroxypyrid-4-one (1.1) in thalassemia major. Blood 1992;80:593-599.
9. HOFFBRAND AV., AL-REFAIE F, DAVIS B, SIRITANAKATKUL N.M, JACKSON BEA., COCHRANE J, PRESCOTT E, WONKE B. Long term trial of deferiprone in 51 transfusions-dependent iron overloaded patients. Blood 1998;91:295-300.
10. OLIVIERI NE, BRITTENHAM GM., MATSUI D, BERKOVITCH M, BLENDIS LM., CAMERON RG., MCCLELLAND RA., BURT AD, FLEMING KA. Long term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-423.
11. COHEN AR., GALANELLO R, PIGA A, PALMA AD, VULLO C, TRICTA F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol 2000;108:305-312.
12. KONTOGHIORGHES GJ, ALDOURI MA, SHEPPARD L, HOFFBRAND AV. 1,2 Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;1:1294-1295.
13. BERKOVITCH M, LAXER RM, INMAN R, KOREAN G, PRITZKER KPH, FRITZLER MJ, OLIVIERI NF. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994;343:1471-1472.
14. KONTOGHIORGHES GJ, NASSERI-SINA P, GODDARD JG, BARR JM, NORTEY P, SHEPPARD LN. Safety of oral iron chelator L1. Lancet 1989;2:457-458.
15. PORTER JB, HOYES KP, ABEYSINGHE R, BROOKS PN, HUEHNS ER, HIDER RC. Comparison of the subacute toxicity and efficacy of 3-hydroxypyrid-4-one iron chelators in overloaded and non-overloaded mice. Blood 1991;78:2727-2734.
16. BERDOUKAS V, BENTLEYM P, FROST H, SCHNEBLI HP. Toxicity of oral iron chelator L1. Lancet 1993;341:1088.
17. AL-REFAIE EN, VEYS PA, WILKES S, WONKE B, HOFFBRAND AV. Agranulocytosis in a patient with thalasseaemia major during treatment with the oral iron chelator. 1.2 dimethyl-3-hydrozypyrid-4-one. Acta Haematol 1993;89:86-90.
18. AL-REFAIE EN, WONKE B, HOFFBRAND AV. Deferiprone-associated myelotoxicity. Eur J Haematol 1994;53:298-301.
19. CUNNINGHAM JM, AL REFAIE FN, HUNTER AE, SHEPPARD LN, HOFFBRAND AV. Differential toxicity of alpha-ketohydroxypyridine iron chelators and desferrioxamine to human haematopoietic precursors in vitro. Eur J Haematol 1994;52:176-179.
20. HOFFBRAND AV. Oral iron chelation. Semin Haematol 1996;33:1-8.